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Summary
Background Whether surgery is beneﬁ cial for patients with asymptomatic carotid stenosis is controversial. Better 
methods of identifying patients who are likely to develop stroke would improve the risk–beneﬁ t ratio for carotid 
endarterectomy. We aimed to investigate whether detection of asymptomatic embolic signals by use of transcranial 
doppler (TCD) could predict stroke risk in patients with asymptomatic carotid stenosis.
Methods The Asymptomatic Carotid Emboli Study (ACES) was a prospective observational study in patients with 
asymptomatic carotid stenosis of at least 70% from 26 centres worldwide. To detect the presence of embolic signals, 
patients had two 1 h TCD recordings from the ipsilateral middle cerebral artery at baseline and one 1 h recording at 6, 
12, and 18 months. Patients were followed up for 2 years. The primary endpoint was ipsilateral stroke and transient 
ischaemic attack. All recordings were analysed centrally by investigators masked to patient identity. 
Findings 482 patients were recruited, of whom 467 had evaluable recordings. Embolic signals were present in 77 of 
467 patients at baseline. The hazard ratio for the risk of ipsilateral stroke and transient ischaemic attack from baseline 
to 2 years in patients with embolic signals compared with those without was 2·54 (95% CI 1·20–5·36; p=0·015). For 
ipsilateral stroke alone, the hazard ratio was 5·57 (1·61–19·32; p=0·007). The absolute annual risk of ipsilateral 
stroke or transient ischaemic attack between baseline and 2 years was 7·13% in patients with embolic signals and 
3·04% in those without, and for ipsilateral stroke was 3·62% in patients with embolic signals and 0·70% in those 
without. The hazard ratio for the risk of ipsilateral stroke and transient ischaemic attack for patients who had embolic 
signals on the recording preceding the next 6-month follow-up compared with those who did not was 2·63 (95% CI 
1·01–6·88; p=0·049), and for ipsilateral stroke alone the hazard ratio was 6·37 (1·59–25·57; p=0·009). Controlling 
for antiplatelet therapy, degree of stenosis, and other risk factors did not alter the results. 
Interpretation Detection of asymptomatic embolisation on TCD can be used to identify patients with asymptomatic 
carotid stenosis who are at a higher risk of stroke and transient ischaemic attack, and also those with a low absolute 
stroke risk. Assessment of the presence of embolic signals on TCD might be useful in the selection of patients with 
asymptomatic carotid stenosis who are likely to beneﬁ t from endarterectomy. 
Funding British Heart Foundation.
Background
About 15% of strokes are caused by carotid artery 
stenosis. In patients with symptomatic carotid stenosis 
greater than 50–70%, carotid endarterectomy reduces 
ipsilateral stroke risk by about 75%1 and is generally 
accepted as being cost eﬀ ective. However, the situation 
in patients with asymptomatic carotid stenosis is less 
clear. Asymptomatic carotid stenosis is more benign 
than symptomatic carotid stenosis and has an ipsilateral 
stroke risk of 2% or less per year.2 Two large randomised 
trials, the Asymptomatic Carotid Atherosclerosis Study 
(ACAS)3 and the Asymptomatic Carotid Surgery Trial 
(ACST),4 reported that about 32 patients needed to have 
carotid endarterectomy to prevent disabling stroke or 
death in one patient over a 5-year period. The cost-
eﬀ ectiveness of surgery for asymptomatic carotid 
stenosis has been questioned,5 and recently the beneﬁ t 
of surgery has been suggested to be even less because of 
the availability of more eﬀ ective medical therapies.6,7 
Nevertheless, asymptomatic carotid stenosis accounts 
for a large burden of stroke. Only 15% of strokes are 
preceded by transient ischaemic attack (TIA) and 
therefore waiting for stenoses to become symptomatic 
fails to prevent most strokes caused by carotid stenosis. 
Risk–beneﬁ t and cost–beneﬁ t ratios of carotid 
endarterectomy in asymptomatic carotid stenosis would 
be improved if surgery was only done in patients with 
asymptomatic carotid stenosis who are at particularly 
high risk of stroke.8 In patients with symptomatic carotid 
stenosis, the stroke risk increases markedly over the 
few months after symptom onset, and the mechanism of 
stroke is believed to be primarily embolic.9 If clinical 
embolism is a good predictor of the subsequent stroke 
risk, asymptomatic cerebral emboli might also predict 
clinical stroke risk. Transcranial doppler ultrasound 
(TCD) is a non-invasive technique that can be used to 
detect circulating emboli. These emboli appear as short-
direction, high-intensity embolic signals and are 
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accompanied by a characteristic chirping sound. This 
technique of detecting circulating emboli has high 
sensitivity and speciﬁ city in vivo10 and in vitro.11
In patients with symptomatic carotid stenosis, the 
presence of embolic signals is an independent predictor 
of future stroke risk.12–14 Detection of embolic signals on 
TCD might be similarly predictive in asymptomatic 
carotid stenosis, but previous studies have been 
inconclusive and have reported diﬀ erent results.13,15,16 We 
established the Asymptomatic Carotid Emboli Study 
(ACES) to assess whether detection of asymptomatic 
embolic signals by use of TCD could predict stroke risk 
in patients with asymptomatic carotid stenosis.
Methods
Patients
ACES was a multicentre, international, prospective 
observational study. The full protocol has been published 
previously.17 Patients were enrolled between July, 1999, and 
August, 2007. Patients from 26 centres worldwide were 
included in the study. Inclusion criteria were at least 70% 
carotid stenosis, assessed by ultrasound, with no 
symptoms in the carotid artery territory for at least 2 years. 
If patients had previously had symptoms in the 
contralateral carotid artery territory or in the vertebrobasilar 
territory, they were eligible if those symptoms occurred 
more than 2 years ago. Patients with contralateral carotid 
endarterectomy were eligible 1 year after endarterectomy, 
assuming that they had been asymptomatic in the territory 
of the operated artery since the operation.
Exclusion criteria were other disease likely to limit 
life expectancy to less than 3 years; patient, physician, 
or surgeon unwilling to manage asymptomatic carotid 
stenosis medically; absence of an acoustic window 
necessary for TCD; and presence of non-biological 
prosthetic heart valves (because these can be associated 
with large numbers of presumed gaseous embolic 
signals18). 
Procedures 
At baseline, two 1 h TCD recordings, separated by 1 week, 
were taken from the ipsilateral middle cerebral artery. In 
symptomatic carotid stenosis, the risk of recurrent stroke 
declines rapidly to a low level by 6 months;1 therefore, 
wherever possible, we did 1 h repeat TCD recordings at 
the 6, 12, and 18 month follow-up visits to ﬁ nd out 
whether the presence of embolic signals at the start of 
each 6-month period predicted risk over the subsequent 
6 months. 
A standard TCD recording protocol was followed by all 
centres, which was based on the recommendations of the 
International Consensus Group on Microembolus 
Detection.19 A 2 MHz transducer was used to insonate the 
middle cerebral artery ipsilateral to the asymptomatic 
carotid stenosis at a depth of between 45 mm and 55 mm. 
A standard axial sample volume of 5 mm was used. All 
embolic signal data were recorded onto digital audiotape 
and analysed centrally by investigators who were masked 
to clinical information. For central data analysis, the audio 
signal was played back into the same doppler machine 
(Pioneer, EME/Nicolet, Madison, USA) with standard 
settings, and fast Fourier transform spectral analysis was 
done with an overlap of at least 60%. Standard consensus 
criteria on embolic signal identiﬁ cation were used in 
addition to an intensity threshold of 7 dB.20 Embolic 
signals were identiﬁ ed visually and audibly. All potential 
embolic signals were then reviewed by a second observer 
(HSM) to ensure consistency in reporting of whether or 
not signals were present. 
Cardiovascular risk factors were recorded at study entry 
and brain imaging (CT or MRI) was done. In cases of 
stroke or TIA during follow-up, repeat brain CT or MRI 
was done. In addition, all patients had carotid duplex 
ultrasound at entry and at 12 months, which was done 
according to a standard protocol17 and recorded onto 
videotape for central image analysis. 
All patients were assessed for hypertension, which was 
deﬁ ned as taking antihypertensive drugs, systolic blood 
pressure over 140 mm Hg, or diastolic blood pressure 
over 90 mm Hg. We also recorded whether patients had 
diabetes mellitus, classed as a clinical diagnosis of type 1 
or type 2 diabetes. Patients were deﬁ ned as having 
ischaemic heart disease if they had a history of angina or 
myocardial infarction and as having peripheral vascular 
disease if they had a history of symptomatic disease. 
Smoking history (present, previous, or never) was also 
recorded. Atrial ﬁ brillation was recorded as being present 
if there was a past history of it, or if it was present on 
electrocardiogram at entry. We noted all drugs each 
patient was receiving at each follow-up visit. 
The primary endpoint was ipsilateral TIA and stroke. 
Secondary endpoints were ipsilateral stroke, any stroke, 
and any stroke or cardiovascular death. All endpoints 
were centrally assessed by review of clinical details and 
brain imaging by investigators who were masked to the 
results of the embolic signals recordings. 
The primary study hypothesis was that the presence of 
embolic signals (deﬁ ned as at least one embolic signal on 
TCD) on recordings at study entry would predict ipsilateral 
TIA and stroke risk over the following 2 years. The 
secondary hypothesis was that the presence of embolic 
signals on a 1 h recording at baseline or at 6, 12, or 
18 months predicted ipsilateral TIA and stroke risk over 
the subsequent 6-month period. 
All patients gave written informed consent and the 
study was approved by the local ethics committees.
Statistical analysis
Because of the paucity of data from large patient groups 
on the prevalence of embolic signals in asymptomatic 
carotid stenosis at the time of study design, sample size 
calculations were revised in year 3 of the study (March, 
2003) by use of interim analysis of baseline recordings 
from the ﬁ rst 132 patients in whom both ﬁ rst and second 
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initial recordings had been analysed.17 The investigators 
remained masked to patient identity during this analysis. 
At this timepoint, 28 of 132 patients had embolic signals 
during either of two 1 h baseline recordings. We therefore 
used a prevalence of 20% in calculations for the primary 
hypothesis. At this interim timepoint, the 2-year 
combined ipsilateral stroke and TIA rate was 6·6%. The 
following assumption was made: the risk of stroke or 
TIA in patients with embolic signals is three-times that 
seen in unselected asymptomatic carotid stenosis. A 
relative risk of 3·0 was used because this would be a 
clinically useful level of relative risk for selection of 
patients for endarterectomy. For sample size calculations, 
a power of 0·9 and p value of 0·05 was used. Using these 
values, a sample size of 440 would be needed to answer 
our primary hypothesis. Assuming a dropout of 8%, the 
required sample size was increased to 478. We therefore 
chose a total sample size of 480.
For the secondary hypothesis, we used the ﬁ rst of the 
entry recordings and the 1 h recordings made at the 6, 12, 
and 18 month follow-up visits from 132 patients. Based 
on prospective data after clinical (ie, symptomatic) emboli 
in patients with carotid stenosis,9 we assumed that 40% 
of clinical events would occur in the ﬁ rst 6 months in 
patients with embolic signals. If each patient’s exposure 
at 6, 12, and 18 months was reclassiﬁ ed according to the 
presence or absence of embolic signals at these 
timepoints, then the risk ratio that we would need to 
detect is RR1=1·6×RR, where RR is the risk ratio over the 
whole 2-year period. The previous risk ratio of 3·0 
corresponds to a new RR1 of 4·8. From our interim 
analysis, 16 of 132 patients had embolic signals on the 
ﬁ rst of the two baseline recordings and we therefore 
assumed a prevalence of 10% for our power calculations. 
Using these values, a sample size of 270 would be needed 
to answer our secondary hypothesis. Assuming that 80% 
of patients would have repeat recordings, the required 
sample size increased from 270 to 338. In addition, 
assuming a dropout of 8%, the required sample size was 
increased to 367. Further details on power calculations 
are presented in the methodology paper.17 
We investigated whether the presence of embolic 
signals predicted ipsilateral stroke or TIA by use of 
Kaplan-Meier survival analysis to enable data from 
patients who did not complete the full 2-year study 
protocol to be included. For each outcome, event rates 
per 100 person-years were calculated and used to estimate 
the absolute annual risk using the formula: annual 
risk=(1–(exp(–event rate×time)). Hazard ratios and their 
95% CIs for the presence of embolic signals were 
estimated using Cox proportional hazard regression 
models. Age and sex were controlled for in all models 
and variables that were associated with embolic signals at 
baseline were also controlled for. Hazard ratios for 
patients with embolic signals compared with those 
without at baseline and 6, 12, and 18 months for the risk 
of having an endpoint over the subsequent 6-month 
period were estimated using time-dependent proportional 
hazards regression models with the same adjustments as 
described earlier. 
The relation between embolic signals at baseline and 
clinical parameters has been previously published.17 In 
brief, the use of antiplatelet drugs was the only 
independent predictor of embolic signals at baseline 
(odds ratio 0·37, 95% CI 0·19–0·72, p=0·003) after 
controlling for age, sex, hypertension, diabetes, current 
smoking, lipid-lowering agents, and antihypertensive 
drugs. Therefore, antiplatelet use was additionally 
controlled for in the analyses.
We did a meta-analysis combining the ACES results 
with those from other prospective studies that reported 
the relation between the presence of embolic signals and 
ipsilateral stroke risk and also the relation with ipsilateral 
Patients with 
ACS (n=482)
Age (years) 71·5 (8·1)
Women 125 (26%)
Smoking
Current 70 (15%)
Previous 224 (46%)
Never 188 (39%)
Hypertension 433 (90%)
Diabetes mellitus 99 (21%)
Ischaemic heart disease 178 (40%)
Atrial ﬁ brillation 35 (7%)
Carotid artery stenosis
<70% 1 (0%)
70–79% 244 (51%)
80–89% 138 (29%)
90–99% 99 (21%)
Contralateral carotid stenosis ≥70%* 94 (20%)
History of ipsilateral ischaemia in study artery territory 37 (8%)
Data are mean (SD) or number (%). *472 patients with data available. 
ACS=asymptomatic carotid stenosis.
Table 1: Demographics and baseline characteristics
Primary endpoint Secondary endpoint
Ipsilateral stroke 
or TIA
Ipsilateral 
stroke
Any stroke Any stroke or 
cardiovascular death
Primary analysis 
No embolic signals (n=390) 22 5 13 31
Embolic signals present (n=77) 10 5 5 6
Total 32 10 18 37
Secondary analysis
No embolic signals (n=1333) 25 6 14 20
Embolic signals present (n=111) 5 3 3 5
Total 30 9 17 25
TIA=transient ischaemic attack.
Table 2: Primary and secondary endpoints
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stroke and TIA, using previously described methods.13 In 
brief, Medline, Embase, and PubMed were searched 
between Jan 1, 1990, and Feb 10, 2010. Only articles in 
English that reported results in human beings were 
included. Search terms were (transcranial doppler OR 
TCD OR ultrasound OR ultrasonography) AND (embolic 
signals OR HITS OR emboli OR cerebral embolism OR 
embolic particles OR MES OR microembolic signals) 
AND (stroke OR transient ischemic attack OR transient 
ischaemic attack OR amaurosis fugax OR death). 
Reference lists of articles fulﬁ lling the inclusion criteria 
and reviews were also searched for relevant references. 
Data were only included from prospective studies. Case 
series including fewer than ﬁ ve patients were excluded. 
Data from each study were extracted independently by 
two researchers, and meta-analyses were done using 
RevMan5 software by use of a random eﬀ ects model. 
Role of the funding source 
The sponsor had no role in study design, data collection, 
data analysis, data interpretation, writing of the report, or 
in the decision to submit the paper for publication. HSM 
had full access to all data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
We recruited 482 patients with asymptomatic carotid 
stenosis. Five patients were excluded for the following 
reasons: two had mechanical prosthetic heart valves, one 
had stenosis less than 70%, one dropped out before any 
TCD recording, and one had unpredictable TCD 
recordings because of a poor acoustic window. Baseline 
demographics and cardiovascular risk factors of all 
recruited patients are shown in table 1. 
The ﬁ rst baseline TCD recording was done in all 
477 patients, and 459 of the recordings could be analysed. 
The second baseline TCD recording was done in 425 of 
477 patients, and 407 of the recordings could be analysed. 
467 patients had at least one baseline recording of 
suﬃ  cient quality for embolic signal analysis. 48 of 459 
(10%) patients had embolic signals on recording 1 and 
44 of 407 (11%) had embolic signals on recording 2. 
399 patients had both baseline recordings: of these, 
43 had embolic signals on the ﬁ rst recording and 43 on 
the second recording. 15 of 43 patients had embolic 
signals on both recordings and 328 of 356 patients did 
not have embolic signals on either recording. There was 
a signiﬁ cant association between patients having similar 
embolic signals status on the two recordings (p<0·0001). 
At baseline, 77 of 467 patients had embolic signals on 
either of the two baseline recordings. The mean number 
of embolic signals in patients with embolic signals 
detected was 2·63 (median 1, range 1–20) on recording 1 
and 2·23 (2, 1–11) on recording 2. 
There were 32 primary endpoints during follow-up 
(26 ipsilateral TIAs and six ipsilateral strokes; table 2). 
Four of the 26 patients who had ipsilateral TIA later had 
ipsilateral stroke; thus, there was a total of ten ipsilateral 
strokes during follow-up. The secondary endpoint of any 
stroke occurred in 18 patients, and 37 had any stroke or 
cardiovascular death. During follow-up, 34 patients had 
carotid endarterectomy: 16 after ipsilateral TIA, one after 
ipsilateral stroke, and 17 for asymptomatic stenosis.
The hazard ratio for the risk of ipsilateral stroke and TIA 
from baseline to 2 years for patients with embolic signals 
at baseline compared with those without was 2·54 (95% CI 
1·20–5·36; p=0·015; table 3); after controlling for presence 
versus absence of antiplatelet therapy at baseline, the 
hazard ratio was 2·39 (1·12–5·11; p=0·025). The absolute 
annual risk of ipsilateral stroke or TIA was 7·13% in 
patients with embolic signals and 3·04% in patients 
without embolic signals. The hazard ratio for the risk of 
ipsilateral stroke alone at 2 years for patients with embolic 
signals at baseline compared with those without was 5·57 
Number 
of events
Person-years Event rate 
(per 100 person-years)
Adjusted for age and sex Adjusted for age, sex, and 
antiplatelet therapy
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Ipsilateral stroke and TIA
Embolic signals absent 22 713·1 3·09 1·0 1·0
Embolic signals present 10 135·0 7·40 2·54 (1·20–5·36) 0·015 2·39 (1·12–5·11) 0·025
Ipsilateral stroke
Embolic signals absent 5 716·3 0·70 1·0 1·0
Embolic signals present 5 135·6 3·69 5·57 (1·61–19·32) 0·007 5·90 (1·68–20·72) 0·006
Any stroke
Embolic signals absent 13 714·5 1·82 1·0 1·0
Embolic signals present 5 135·6 3·69 2·19 (0·78–6·15) 0·14 2·36 (0·83–6·67) 0·11
Any stroke or cardiovascular death
Embolic signals absent 31 714·8 4·34 1·0 1·0
Embolic signals present 6 135·6 4·43 1·08 (0·45–2·59) 0·87 1·12 (0·46–2·71) 0·80
TIA=transient ischaemic attack.
Table 3: Primary analysis 
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(1·61–19·32; p=0·007); after controlling for baseline 
antiplatelet therapy, the hazard ratio was 5·90 (1·68–20·72; 
p=0·006). The absolute annual risk of ipsilateral stroke 
was 3·62% in patients with embolic signals and 0·70% for 
those without. The negative predictive value was 94·4% 
and the positive predictive value was 13·0%. Controlling 
for degree of stenosis and other risk factors (as speciﬁ ed 
in the protocol) did not signiﬁ cantly alter the results 
(table 4). In addition, there was no eﬀ ect of the use of 
statins at baseline (test for interaction p=0·53). There was 
no association between the presence of embolic signals 
and risk of any stroke (p=0·14), or any stroke and 
cardiovascular death (p=0·87; table 3). Kaplan-Meier 
survival plots for the diﬀ erent outcomes are shown 
in ﬁ gure 1. 
For the analysis of 6-monthly time periods, recordings 
of suﬃ  cient quality for analysis were available for 
1444 6-monthly periods from 470 patients (233 had four 
recordings, 102 had three recordings, 71 had two 
recordings, and 64 had one recording) and embolic 
signals were present in 111 of these. The hazard ratio 
for the risk of ipsilateral stroke and TIA for patients 
with embolic signals at the recording preceding the 
next 6-month period compared with those without 
embolic signals at that timepoint was 2·63 (95% CI 
1·01–6·88; p=0·049; table 5); after controlling for 
presence versus absence of antiplatelet therapy at time 
of the TCD recording, the hazard ratio was 2·65 
(1·01–7·00; p=0·049). The absolute annual risk of 
ipsilateral stroke or TIA was 9·04% in patients with 
embolic signals and 3·66% in those without. The 
hazard ratio for the risk of ipsilateral stroke alone for 
patients with embolic signals at the recording preceding 
the next 6-month period compared with those without 
embolic signals at that timepoint was 6·37 (1·59–25·57; 
p=0·009); after controlling for antiplatelet therapy at 
time of the TCD recording, the hazard ratio was 6·56 
(1·60–26·86; p=0·009). Controlling for degree of 
stenosis did not alter the results (table 6). The absolute 
annual risk of ipsilateral stroke was 5·50% in patients 
with embolic signals and 0·89% in those without 
embolic signals. The positive predictive value was 
94·2% and the negative predictive value was 14·6%. 
The hazard ratio for the risk of any stroke for patients 
with embolic signals at the recording preceding the 
next 6-month period compared with those without 
embolic signals at that timepoint was 2·88 (0·83–10·04; 
p=0·10) and for the risk of any stroke or cardiovascular 
death the hazard ratio was 3·37 (1·26–8·98; p=0·015; 
table 5). Kaplan-Meier survival plots for the diﬀ erent 
outcomes are shown in ﬁ gure 2. 
We did a meta-analysis of the results of the previous 
published studies15,16,21–23 as well as the primary endpoint 
data (2-year follow-up analysis) from ACES (ﬁ gure 3). 
Data were available for a total of 1144 patients. The cut-oﬀ  
for deﬁ ning a patient as having embolic signals varied: 
one or more embolic signals for ACES and three other 
studies16,21,22 and at least two embolic signals for two 
studies.15,23 The hazard ratio for the risk of ipsilateral 
stroke for those with embolic signals compared with 
those without was 6·63 (95% CI 2·85–15·44; p<0·0001) 
and there was no heterogeneity between studies (p=0·33). 
The hazard ratio for the risk of ipsilateral stroke and TIA 
for those with embolic signals compared with those 
without was 7·57 (2·32–24·69; p=0·0008), but there was 
heterogeneity in this analysis (p=0·002).
Discussion
In this international multicentre study, the presence of 
asymptomatic embolisation, detected by TCD, predicted 
subsequent ipsilateral stroke and TIA and also ipsilateral 
stroke alone. This suggests that TCD might be useful to 
Ipsilateral stroke and TIA Ipsilateral stroke 
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age and sex 2·54 (1·20–5·36) 0·015 5·57 (1·61–19·32) 0·007
Age, sex, and antiplatelet therapy 2·39 (1·12–5·11) 0·025 5·90 (1·68–20·72) 0·006
Age, sex, and hypertension 2·73 (1·29–5·79) 0·009 5·47 (1·57–19·04) 0·008
Age, sex, and diabetes 2·48 (1·17–5·25) 0·017 5·59 (1·61–19·43) 0·007
Age, sex, and smoking 2·54 (1·20–5·40) 0·015 5·24 (1·49–18·35) 0·010
Age, sex, and degree of stenosis 2·53 (1·20–5·37) 0·015 5·08 (1·45–17·76) 0·011
TIA=transient ischaemic attack.
Table 4: Association between embolic signals at baseline and risk of stroke or TIA over subsequent 2 years 
with adjustment for a-priori risk factors 
Figure 1: Survival plots for the association between the presence of embolic signals and cumulative event 
rates for the analysis of whether embolic signals at baseline predict risk
77 patients had embolic signals and 390 did not. TIA=transient ischaemic attack.
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identify patients with asymptomatic carotid stenosis 
who are at increased risk of stroke or TIA, and also to 
identify patients at low risk in whom surgical 
intervention will not be beneﬁ cial. The technique 
enabled identiﬁ cation of a group of patients who did 
not have embolic signals in whom the annual risk of 
stroke was less than 1%; at this level of risk carotid 
endarterectomy is not associated with beneﬁ t and might 
actually incur risk.6 
Previous studies in symptomatic carotid stenosis have 
shown that embolic signals predict future stroke risk.12,13 
However, data from asymptomatic carotid stenosis, in 
which there is a greater potential clinical application, 
have been less conclusive.13,15,16 One study in 319 patients, 
of whom 210 were available for analysis at 2 years, 
reported a signiﬁ cant association between embolic 
signals at baseline and future risk of stroke and TIA.15 
In this single-centre study, analysis of embolic signals 
was done online, rather than by subsequent masked 
analysis as in ACES; however, the proportion of 
individuals with embolic signals was similar to that in 
ACES (10% on a single baseline recording). A second 
study in 202 individuals with subsequent oﬄ  ine analysis 
of embolic signals found no association between 
embolic signals at baseline and subsequent stroke risk.16 
Repeat recordings were done in some individuals at 
6-monthly intervals and there seemed to be fewer events 
in patients who consistently did not have embolic 
signals. The hazard ratio for stroke associated with the 
presence of embolic signals in ACES was midway 
between these two studies. Meta-analysis of the results 
of the primary analysis from ACES with all previous 
studies showed a signiﬁ cant association between 
embolic signals and subsequent stroke risk. Meta-
analysis also showed a signiﬁ cant association between 
embolic signals and the combined endpoint of stroke 
and TIA, although there was heterogeneity between 
studies for this analysis. 
Optimal management of asymptomatic carotid 
stenosis remains controversial, and practices vary 
between diﬀ erent clinicians and in diﬀ erent countries. 
Data from large randomised trials have shown a 
signiﬁ cant eﬀ ect of endarterectomy in preventing 
future stroke, but with a small absolute beneﬁ t.3,4 Recent 
analyses6,7 have reported that, with improved medical 
treatment, the annual risk of stroke in patients with 
asymptomatic carotid stenosis is lower than that 
reported in the carotid endarterectomy trials (nearer to 
1% in these trials compared with 2·3% in ACAS),3 
which further reduces the beneﬁ t of surgical 
intervention. This is consistent with the annual risk of 
ipsilateral stroke of 1·2% (ten ipsilateral strokes over 
2 years) reported in ACES. This improvement in natural 
history with better medical therapy might make surgical 
intervention hazardous.6 Carotid stenting has been 
suggested as an alternative to endarterectomy, but as 
yet there are no data showing it is safer than 
endarterectomy for asymptomatic carotid stenosis. 
Ipsilateral stroke and TIA Ipsilateral stroke 
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age and sex 2·63 (1·01–6·88) 0·049 6·37 (1·59–25·57) 0·009
Age, sex, and antiplatelet therapy 2·65 (1·01–7·00) 0·049 6·56 (1·60–26·86) 0·009
Age, sex, and hypertension 2·62 (1·00–6·85) 0·050 6·48 (1·62–25·99) 0·008
Age, sex, and diabetes 2·64 (1·01–6·90) 0·048 6·37 (1·59–25·55) 0·009
Age, sex, and smoking 2·63 (1·01–6·86) 0·049 6·36 (1·58–25·52) 0·009
Age, sex, and degree of stenosis 2·60 (1·00–6·82) 0·051 6·03 (1·49–24·40) 0·012
TIA=transient ischaemic attack.
Table 6: Embolic signals at the start of each 6-month period and risk over the subsequent 6 months
Number 
of events
Person-years Event rate 
(per 100 person-years)
Adjusted for age and sex Adjusted for age, sex, and 
antiplatelet therapy
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Ipsilateral stroke and TIA
Embolic signals absent 25 670·9 3·73 1·0 1·0
Embolic signals present 5 52·8 9·47 2·63 (1·01–6·88) 0·049 2·65 (1·01–7·00) 0·049
Ipsilateral stroke
Embolic signals absent 6 673·8 0·89 1·0 1·0
Embolic signals present 3 53·0 5·66 6·37 (1·59–25·57) 0·009 6·56 (1·60–26·86) 0·009
Any stroke
Embolic signals absent 14 672·1 2·08 1·0 1·0
Embolic signals present 3 53·0 5·66 2·88 (0·83–10·04) 0·10 3·10 (0·88–10·89) 0·078
Any stroke or cardiovascular death
Embolic signals absent 20 672·7 2·97 1·0 1·0
Embolic signals present 5 53·0 9·43 3·37 (1·26–8·98) 0·015 3·52 (1·31–9·47) 0·013
TIA=transient ischaemic attack.
Table 5: Secondary analysis 
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Despite the small absolute beneﬁ t from intervention, 
asymptomatic carotid stenosis accounts for a substantial 
stroke burden. Most patients with carotid stenosis will 
not have TIA or minor stroke before disabling stroke. 
Therefore, an appealing approach is to identify the small 
group of patients with asymptomatic carotid stenosis and 
high risk of stroke who would beneﬁ t most from surgical 
intervention. Several markers of high risk have been 
suggested, including clinical risk factors, degree of 
carotid stenosis, and plaque characteristics on imaging. 
However, none have been consistently supported by data 
from prospective studies.2 The ACES results show that 
TCD embolic signal detection can be used to identify a 
high-risk group. 
We chose our primary endpoint to allow suﬃ  cient 
numbers of endpoints to detect an association within our 
sample size. However, we were able to also detect an 
association with the more robust endpoint of stroke 
alone. This association was stronger, perhaps because 
diagnosis of stroke is more reliable than that of TIA. The 
risk of further stroke in patients with symptomatic 
carotid stenosis is greatest within the ﬁ rst few weeks and 
rapidly reduces over the ﬁ rst 6 months.9 We hypothesised 
that a similar relation might exist with embolic signals; 
that is, their presence would be associated with an early 
high risk which would rapidly reduce over a period 
of weeks to months. For this reason, we assessed whether 
the presence of embolic signals at the start of each 
6-month period predicted risk over the subsequent 
6 months. This analysis conﬁ rmed associations between 
the presence of embolic signals and subsequent TIA and 
stroke risk, and there was also a signiﬁ cant association 
with the risk of any stroke and cardiovascular death. 
However, the diﬀ erence in hazard ratios between 
prediction over 6 months and our primary analysis of 
prediction over 2 years was small and our results suggest 
that the presence of embolic signals is associated with 
risk over a longer follow-up period. 
An important consideration with any risk stratiﬁ cation 
technique is whether it provides additional information 
over conventional risk factors. Controlling for whether 
the patient was treated with antiplatelet therapy, which 
was associated with the presence of embolic signals at 
baseline, did not markedly alter the association between 
embolic signals and future stroke risk. In addition, 
controlling for other risk factors that were speciﬁ ed in 
the study protocol17 but that were not associated with the 
presence of embolic signals at baseline had little eﬀ ect on 
the associations with stroke and TIA or stroke alone. This 
supports the use of embolic signals as an independent 
predictor of stroke risk. 
ACES is the ﬁ rst prospective, multicentre, international 
study of the predictive value of the detection of embolic 
signals. ACES included over 20 centres from diﬀ erent 
health-care systems, both academic and non-academic, 
and therefore its results are widely applicable. Analysis of 
embolic signals was done centrally by investigators who 
were masked to clinical information, and endpoint 
assessment was done centrally by investigators masked to 
the results of embolic signals analysis. There was only a 
small amount of missing data and no patients were lost to 
follow-up. There is a paucity of large multicentre studies 
evaluating the clinical impact of new neurovascular 
ultrasound techniques, which has resulted in uncertainty 
over their clinical application. However ACES, and other 
multicentre studies on embolic signal detection,14,24 
therapeutic ultrasound,25 and diagnostic ultrasound,26 
show that such multicentre studies are feasible. 
A potential limitation of ACES is that bias could have 
occurred in those cases of asymptomatic carotid stenosis 
where the surgeon was unwilling to enrol the patient, 
which could have led to exclusion of a higher risk group 
of patients. However, embolic signal results were not 
available at the time this decision was made and therefore 
would not have inﬂ uenced the decision as to whether to 
enrol a patient in the study. A second limitation is that 
there were only ten strokes during follow-up, although 
there were 32 ipsilateral strokes or TIA. 
If TCD is to be used as a clinical tool for risk 
stratiﬁ cation, improved methods of automated detection 
of embolic signals are needed. TCD recording itself is 
simple, non-invasive, and widely used in clinical practice 
worldwide. However, review of data for the presence of 
embolic signals is time consuming and relies on trained 
observers. Inter-observer reproducibility studies have 
reported that there is a high reproducibility among 
Figure 2: Survival plots for the association between the presence of embolic signals and cumulative event 
rates for the analysis of whether embolic signals at the start of each 6-month interval predict risk over the 
subsequent 6-month period
111 recordings had embolic signals and 1333 did not. TIA=transient ischaemic attack.
A Primary endpoint: ipsilateral stroke or TIA B Ipsilateral stroke alone
C Any stroke D Any stroke or cardiovascular death
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trained observers in detection of embolic signals, but that 
without adequate training some centres interpret the 
criteria incorrectly.27 The rate of embolisation we detected 
was low, with a median count of one per hour in those 
patients with embolic signals. Therefore, such automated 
systems need to be both sensitive and speciﬁ c. Automated 
systems have been developed that have high sensitivity 
and speciﬁ city for detecting the higher intensity embolic 
signals seen in patients with symptomatic stenosis and 
in the immediate period after carotid endarterectomy.28 
However, these systems were less sensitive to the lower 
intensity embolic signals found in asymptomatic carotid 
stenosis.29 Further work is needed to develop more 
sensitive systems, although there are several promising 
image analysis techniques that could be used in such 
systems. In our study we did all TCD recordings for 1 h. 
Further analysis of ACES data, and in particular an 
individual patient meta-analysis of studies to date, might 
allow us to identify the optimal duration of recording.
In summary, ACES shows that detection of embolic 
signals by TCD can identify groups of patients with 
asymptomatic carotid stenosis who are at low or high 
risk of future stroke. This technique might be a useful 
risk predictor for identifying those patients who might 
beneﬁ t from intervention with carotid endarterectomy.
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